DK2086331T3 - Fremgangsmåder til behandling af neuronale lidelser ved anvendelse af MNTF-peptider og analoger deraf. - Google Patents

Fremgangsmåder til behandling af neuronale lidelser ved anvendelse af MNTF-peptider og analoger deraf.

Info

Publication number
DK2086331T3
DK2086331T3 DK07867451.2T DK07867451T DK2086331T3 DK 2086331 T3 DK2086331 T3 DK 2086331T3 DK 07867451 T DK07867451 T DK 07867451T DK 2086331 T3 DK2086331 T3 DK 2086331T3
Authority
DK
Denmark
Prior art keywords
analogs
methods
neuronal disorders
treating neuronal
mntf peptides
Prior art date
Application number
DK07867451.2T
Other languages
Danish (da)
English (en)
Inventor
Pui-Yuk Dorothy Ko
Mark S Kindy
Original Assignee
Genervon Biopharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genervon Biopharmaceuticals Llc filed Critical Genervon Biopharmaceuticals Llc
Application granted granted Critical
Publication of DK2086331T3 publication Critical patent/DK2086331T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK07867451.2T 2006-11-10 2007-11-13 Fremgangsmåder til behandling af neuronale lidelser ved anvendelse af MNTF-peptider og analoger deraf. DK2086331T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85802206P 2006-11-10 2006-11-10
PCT/US2007/023951 WO2008057609A2 (en) 2006-11-10 2007-11-13 Methods of treating neuronal disorders using mntf peptides and analogs thereof

Publications (1)

Publication Number Publication Date
DK2086331T3 true DK2086331T3 (da) 2013-05-27

Family

ID=39365151

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07867451.2T DK2086331T3 (da) 2006-11-10 2007-11-13 Fremgangsmåder til behandling af neuronale lidelser ved anvendelse af MNTF-peptider og analoger deraf.

Country Status (9)

Country Link
US (1) US8673852B2 (enExample)
EP (1) EP2086331B1 (enExample)
JP (1) JP5336384B2 (enExample)
CN (1) CN101534648B (enExample)
AU (1) AU2007317730B2 (enExample)
CA (1) CA2669658C (enExample)
DK (1) DK2086331T3 (enExample)
ES (1) ES2407454T3 (enExample)
WO (1) WO2008057609A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101951942B (zh) * 2008-02-21 2014-09-03 健能万生物制药公司 Mntf肽组合物及使用方法
MY189079A (en) * 2009-12-11 2022-01-25 Univ Case Western Reserve Insulin analogues with chlorinated amino acids
GB201015569D0 (en) * 2010-09-16 2010-10-27 Medical Res Council Blood assay for prions
WO2016210123A1 (en) 2015-06-26 2016-12-29 Genervon Biopharmaceuticals, LLC Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease
CN110381981A (zh) * 2016-12-23 2019-10-25 健能万生物制药公司 在诊断和治疗阿尔茨海默病中使用gm6的方法
WO2018129421A1 (en) * 2017-01-09 2018-07-12 Genervon Biopharmaceuticals, LLC A promising drug candidate for parkinson's disease
MX2020012532A (es) * 2018-05-31 2021-04-28 Immunity Pharma Ltd Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela).

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841531B2 (en) * 1996-09-27 2005-01-11 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotrophic factors
US6309877B1 (en) * 1996-09-27 2001-10-30 Km Biotech, Inc. Polynucleotides encoding motoneuronotrophic factors
DK1587526T3 (da) * 2003-01-21 2012-02-06 Genervon Biopharmaceuticals Llc MNTF-peptider og sammensætninger og anvendelsesmåder

Also Published As

Publication number Publication date
WO2008057609A4 (en) 2009-01-29
WO2008057609A3 (en) 2008-12-18
HK1137623A1 (en) 2010-08-06
US20090048162A1 (en) 2009-02-19
US8673852B2 (en) 2014-03-18
AU2007317730B2 (en) 2014-01-09
CN101534648A (zh) 2009-09-16
EP2086331A4 (en) 2010-08-25
EP2086331B1 (en) 2013-03-27
WO2008057609A8 (en) 2008-08-28
AU2007317730A1 (en) 2008-05-15
EP2086331A2 (en) 2009-08-12
JP2010509345A (ja) 2010-03-25
CA2669658C (en) 2017-12-12
WO2008057609A2 (en) 2008-05-15
CA2669658A1 (en) 2008-05-15
CN101534648B (zh) 2013-12-11
JP5336384B2 (ja) 2013-11-06
ES2407454T3 (es) 2013-06-12

Similar Documents

Publication Publication Date Title
DK1812110T3 (da) Apparat til behandling af dermatologiske lidelser
DK1948852T3 (da) Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK3689407T3 (da) Apparat til vejrtrækningshjælp
DK2068874T3 (da) Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
DK2310034T3 (da) Peptider til behandling af beta-amyloidose
DK1969099T3 (da) Fremgangsmåde og indretning til behandling af biomasse
DK2240135T3 (da) Apparat til behandling af fedme og reflukssygdom
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
ES2322882B1 (es) Peptidos inhibidores de la exocitosis neuronal.
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
DK2001892T3 (da) Imidazolthiazolforbindelser til behandling af proliferative sygdomme
DK2081669T3 (da) Fremgangsmåde og anordning til fremstilling af granulater
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
DK3457135T3 (da) Behandlingsmuligheder til fabrys sygdom
DK2046362T3 (da) Formulering omfattende valleprotein og hydrolysater til forbedring af muskelrekuperation
DK2865422T3 (da) Alpha-msh-derivater til behandling af fotodermatoser
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK2061485T3 (da) EV576-peptider til anvendelse ved behandling af Guillain-Barré-syndrom
DK1900693T3 (da) Indretning til behandling af ballastvand
DK2066817T3 (da) Molekylære afbrydere og fremgangsmåder til anvendelse deraf
DK2217376T3 (da) Kuvette og fremgangsmåde til anvendelse af denne kuvette
DK1994155T3 (da) Polynukleotider og polypeptidsekvenser involveret i processen for knoglegendannelse.
DK2086331T3 (da) Fremgangsmåder til behandling af neuronale lidelser ved anvendelse af MNTF-peptider og analoger deraf.
DK2012814T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme